CEL-SCI Corporation
CEL-SCI Corporation (NYSE: CVM) is a clinical-stage biotechnology company developing immunotherapies and other treatments that seek to use the immune system against cancer and other diseases. Its lead candidate, Multikine, is an investigational immunotherapy being developed as a presurgical treatment for certain newly… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CEL-SCI Corporation does
In the company’s own words
CEL-SCI Corporation (NYSE: CVM) is a clinical-stage biotechnology company developing immunotherapies and other treatments that seek to use the immune system against cancer and other diseases. Its lead candidate, Multikine, is an investigational immunotherapy being developed as a presurgical treatment for certain newly diagnosed, resectable head and neck cancers, particularly tumors with low PD-L1 expression and no lymph node involvement. CEL-SCI is pursuing a confirmatory registration study after a prior Phase III trial; its candidates have not been approved for sale. The company also develops LEAPS, a peptide-based technology with early-stage candidates for potential rheumatoid arthritis treatment. CEL-SCI’s business is organized around these two development programs, with Multikine its primary focus. The company operates a dedicated manufacturing facility for Multikine clinical production and has licensing and commercialization agreements covering certain international markets, contingent on regulatory approval. CEL-SCI was formed in 1983. Its website is www.cel-sci.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- VIENNA, VA
- Fiscal year end
- September
- CIK
- 725363
- SIC
- 2836
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CEL-SCI Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CEL-SCI Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CEL-SCI Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CEL-SCI Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CEL-SCI Corporation's last four quarterly filings that the numbers alone won't show?”